ANAVEX 2-73 Could Prevent Alzheimer’s Disease in Addition to Modifying and Treating Symptoms February 25, 2015
Amarantus Announces First Alzheimer’s Biomarker Services Collaboration for LymPro Test® with Anavex Life Sciences Corp. February 18, 2015
Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 – Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases February 9, 2015
Mitochondrial protection by the mixed muscarinic/sigma-1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Ab25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model. January 20, 2015
Anavex Doses First Alzheimer’s Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS January 12, 2015
Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor January 6, 2015
Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS December 16, 2014
